Latest Clinical trial Stories
SYDNEY and DURHAM, N.C., March 21, 2013 /PRNewswire/ -- RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced the selection of the Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI), Durham, North Carolina, USA as a site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C. TT-034 is being developed as a potential "one-shot-cure" for Hepatitis C (HCV). "We are very excited to be...
CONSHOHOCKEN, Pa., March 21, 2013 /PRNewswire/ -- ePharmaSolutions, a leading clinical services and eClinical solutions provider, and CenterWatch, a top provider of clinical research business information and the leading online publisher of active clinical trial listings for patients and the public, are partnering to provide sponsors and patients with a novel solution that will increase the opportunities for patients to find trials for which they may qualify. Only 5% of patients who...
Demonstrates Weight Maintenance and Increase in Patient Appetite and Quality Of Life NEW YORK, March 21, 2013 /PRNewswire/ -- Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients,...
New research highlights significant economic benefit of clinical trials in the Lone Star State and opportunities for Texas patients to contribute to medical progress AUSTIN, Texas, March 20, 2013 /PRNewswire/ -- WHO: Sen. Bob Deuell (R) - Greenville; Rep. Jim Murphy (R) - Houston; Tom Kowalski, President, Texas Healthcare and Bioscience Institute; Dr. Curtis Triplitt,...
Companies Demonstrate Power of NextDocs Trial Exchange Built for Microsoft Windows 8 CONSHOHOCKEN, Pa., March 20, 2013 /PRNewswire/ -- NextDocs, the global leader in compliance solutions for the life sciences industry, today demonstrated how its newly launched Trial Exchange solution combined with Windows 8 addresses the critical needs of life sciences companies in securely and efficiently managing clinical trials in today's highly global and mobile operating environments. Trial...
SAN DIEGO, March 19, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2012. Brian M. Culley, Chief Executive Officer, said: "2013 will be an exciting year for Mast Therapeutics. We already have accomplished several key objectives, including initiating a pivotal phase 3 clinical study in sickle cell disease, initiating a thorough QT study of MST-188, identifying multiple new development...
SEATTLE, March 18, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2012. Financial Results Total operating expenses for the three months ended December 31, 2012 were $9.1 million, compared to $11.0...
LONDON and Wilmington, N.C., March 18, 2013 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that SOTIO a.s. has selected Chiltern International Limited to be the CRO that carries out the European part of its phase III global clinical trial entitled VIABLE, which will include 1,170 prostate cancer patients from Europe and the U.S. Under the agreement signed in December 2012, Chiltern will be responsible for providing...
VANCOUVER, March 18, 2013 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today commented on the United States Food and Drug Administration's (FDA) plan to expedite the approval of new treatments for Alzheimer's disease. As reported by the New York Times, drugs in clinical trials would qualify for approval if people with very early-stage Alzheimer's showed even subtle improvement in memory or reasoning tests. ANAVEX 2-73, the company's lead compound for...
LONDON, March 18, 2013 /PRNewswire/ -- The Cure Parkinson's Trust, a charity founded by four people with Parkinson's disease, which is dedicated to finding, facilitating and funding work towards a cure, today welcomes Kenneth Mulvany to the charity as Chairman. Ken Mulvany is an entrepreneur and healthcare industry veteran and brings more than 15 years of business leadership and experience to The Cure Parkinson's Trust. Ken was previously CEO of Proximagen, a UK-based...
